From other sites
at CNBC.com (Aug 19, 2014)
at CNBC.com (Apr 9, 2014)
at CNBC.com (Apr 8, 2014)
at CNBC.com (Apr 8, 2014)
at MarketWatch.com (Dec 27, 2013)
Mon, Dec. 8, 12:37 PM
- Biotech investors are giving Seattle Genetics (SGEN -8.4%) the cold shoulder today on increased volume. It appears that all the love is being directed to the potential of competitors' PD-1 inhibitors in fighting cancer despite the company's presentations at the American Society of Hematology meeting of positive results for Adcetris (brentuximab vedotin), an antibody-drug conjugate directed to CD30 in Hodgkin lymphoma (HL).
- Long-term data from a Phase 1 trial of Adcetris combined with AVD (adriamycin, vinblastine, dacarbazine) demonstrated a 100% overall survival rate at year three and 92% failure-free survival rate at year 3 in frontline HL.
- Adcetris in combination with bendamustine as a second-line therapy demonstrated an objective response rate of 96% and a complete remission rate of 83% in patients with relapsed or refractory HL.
- In a Phase 2 trial in previously untreated HL patients aged 60 and older, Adcetris showed a 93% objective response rate.
- The company is collaborating with Takeda Pharmaceutical Co. (OTCPK:TKPHF) (OTCPK:TKPYY) on the development of the product.
- Previously: Positive results in Adcetris Phase 3 label expansion trial (Sept. 29, 2014)
- PD-1 inhibitor-related tickers: (BMY +0.2%)(FPRX +4.8%)(MRK -0.2%)(CELG +4.2%)(OTCQX:RHHBY -0.5%)(AZN -0.6%)
Mon, Dec. 1, 10:26 AM
- The FDA designates Takeda Pharmaceutical Company's (OTCPK:TKPHF) (OTCPK:TKPYY) investigational oral proteasome inhibitor, ixazomib, a Breakthrough Therapy for the treatment of relapsed or refractory systemic light-chain (AL) amyloidosis. It is the first proteasome inhibitor and the first investigational therapy for AL amyloidosis to receive the status.
- Among the benefits of BTD are more intensive FDA guidance, the involvement of senior agency managers and a rolling review of the NDA.
Tue, Nov. 11, 11:22 AM
- Takeda Pharmaceuticals (OTCPK:TKPHF) (OTCPK:TKPYY) and GE Healthcare form a partnership focused on hepatic fibrosis research and development. Under the terms of the alliance agreement, GE will provide diagnostic imaging technology to Takeda for use in generating a liver stiffness map that the latter is developing as part of its research. The objective is to leverage the strengths of the two companies to develop new therapeutics and diagnostic technologies for liver diseases.
- One goal is to develop a way to measure the relative stiffness of liver tissue without having to perform a biopsy. MR elastography, for example, has the potential to be a reliable non-invasive way to do this.
Tue, Oct. 28, 8:26 AM
- U.S. District Judge Rebecca Doherty agreed withe jury that Takeda (OTCPK:TKPHF) (OTCPK:TKPYY) and Eli Lilly (NYSE:LLY) hid the cancer risks of its diabetes drug Actos (pioglitazone), but cut the punitive damages award from $9B to $36.8M, the maximum a jury could award under current U.S. law. The judge denied the firms' request for a new trial.
- Takeda faces more than 8,000 lawsuits in the U.S. accusing it of mishandling Actos.
Wed, Oct. 22, 11:31 AM
- The European Commission approves privately-held Switzerland-based Ferring Pharmaceuticals' Cortiment (budesonide) for the induction of remission in patients with active mild-to-moderate ulcerative colitis. Budesonide is a locally acting glucocorticosteroid.
- Ferring licensed Cortiment from Cosmo Pharmaceuticals SpA for the EU, Asia (ex-Japan), Australia, Canada, Latin America and Africa. The product is sold under the brand name Uceris in the U.S. by Salix Pharmaceuticals (SLXP -0.2%).
- UC-related tickers: (NASDAQ:VBLX) (RCPT)(OTCPK:TKPHF)(OTCPK:TKPYY +0.2%)(ATHX +2.3%)(SHPG +1.3%)(PFE +0.7%)(ABT -0.4%)(ABBV +1.2%)(CNDO +1.1%)(JNJ +1%)(SGYP -3.2%)
Tue, Oct. 21, 10:52 AM
- The FDA accepts Eli Lilly's NDA for empagliflozin plus immediate-release metformin hydrochloride for the treatment of adults with type 2 diabetes (T2D). The product is part of the Lilly/Boehringer Ingelheim Diabetes alliance portfolio.
- Empagliflozin is a sodium glucose co-transporter-2 inhibitor which removes excess glucose through the urine by blocking glucose reabsorption in the kidney. Metformin decreases the production of glucose in the liver and its absorption in the intestine and improves the body's ability to utilize glucose.
- The FDA approved Jardiance (empagliflozin) as an adjunct to diet and exercise to improve glycemic control in adults with T2D in August 2014. Metformin has been in clinical use for many years.
- Diabetes-related tickers: (JNJ +0.4%)(OTCQB:ISLT)(OTCQB:BTHE +20%)(VTAE +2.5%)(NVO +0.5%)(MRK +0.9%)(NASDAQ:VKTX)(HPTX +0.4%)(ABT +1.2%)(OTCPK:TKPHF)(OTCPK:TKPYY -0.5%)(MDT +1.7%)(SNY -0.2%)(OTCQB:SNYNF -0.5%)(MNKD +2.4%)(ALR +1.4%)(TNDM +3%)
Wed, Oct. 15, 10:33 AM
- Orexigen Therapeutics (OREX +6.4%) earns a $70M milestone payment from Takeda Pharmaceuticals (OTCPK:TKPHF -0.8%)(OTCPK:TKPYY -0.7%) triggered by the shipment of Contrave (naltrexone HCI and bupropion HCI extended release) to pharmacy wholesalers in preparation for commercial launch. It earned a $30M milestone triggered by FDA approval on October 7.
- Orexigen expects to end 2014 with ~$190M in quick assets.
Thu, Oct. 9, 1:29 PM
- The FDA approves Takeda Pharmaceutical Compnay's (OTCPK:TKPHF)(OTCPK:TKPYY -1.2%) Velcade (bortezomib) injection for treatment-naive patients with mantle cell lymphoma (MCL). Velcade is the first treatment approved in the U.S. for this indication.
- The product was previously approved for the treatment of multiple myeloma and relapsed mantle cell lymphoma.
- Velcade is co-developed by Milliennium/Takeda and Janssen Pharmaceutical Cos. Millennium is responsible for its commercialization in the U.S. and Janssen ex-U.S.
Tue, Oct. 7, 9:54 AM
- Menlo Park, CA-based Virobay (VBAY) is set for its IPO of 3.8M shares at $12 - 14.
- The clinical stage biopharmaceutical firm develops drugs based on its cysteine cathepsin platform. Cysteine cathepsins are important enzymes in the biology of many diseases. The company believes that inhibiting these enzymes produces safer, more effective therapies. It currently focuses its efforts on inhibitors of cathepsins S and B.
- Its lead product candidates are cathepsin S inhibitors: VBY-036 for neuropathic pain and Crohn's disease and VBY-891 for psoriasis. Phase 2 development for all three indications should commence in 1H 2015 which means that meaningful product revenues are far in the distance.
- In 2013, the company generated $9.9M in collaboration revenue. Its operating loss was ($2.3M). In 1H 2015, collaboration revenue dropped to $1.1M and the loss from operations increased to ($3.6M).
- Crohn's disease-related tickers: (ABBV -1.6%)(MRK -1.2%)(RDHL +0.4%)(VBLX)(OTCPK:TKPHF)(OTCPK:TKPYY)(CNDO +1.1%)(OTCQB:SNGX)(PSTI +2.3%)
- Neuropathic pain-related tickers: (DARA -4.4%)(AVNR -3.4%)(ZLCS +0.9%)(IPCI -2%)(BLRX -1.9%)(MNOV +0.6%)(PFE -0.3%)(OTCPK:NGSX)
- Psoriasis-related tickers: (DERM -0.5%)(NVS -2.5%)(CELG -1.4%)(LLY -1.3%)(CANF -2.3%)(IDRA -1.4%)(JNJ -0.8%)(XNPT +0.5%)(HSP -0.2%)
Fri, Oct. 3, 4:34 AM
- From the press release: "Takeda (OTCPK:TKPHF, OTCPK:TKPYY) has previously openly addressed through announcements and press conferences that, regarding the CASE-J study, an investigator-initiated sponsored research (IISR) related to the Takeda's hypertension medicine Blopress (candesartan cilexetil), certain inappropriate promotional activities utilizing the results of this research were found to have occurred." See the PR for its plans for preventing further inappropriate promotion.
- "For related directors, depending on their individual scope of responsibility, a reduction of monthly remuneration within the range of 5% to 20% will be imposed for three months."
Fri, May. 23, 2:39 PM
- Takeda Pharmaceuticals (TKPHF, TKPYY) yesterday was found not liable for the bladder cancer of two women who used its Actos diabetes medication, as a Nevada jury agreed with the company that the drug did not cause the women’s disease.
- A jury last month ordered Takeda and partner Eli Lilly (LLY) to pay more than $9B in damages to a plaintiff - Takeda is appealing the verdict - but the company has won the other five cases that have gone to trial over Actos' alleged link to bladder cancer.
- Takeda still faces claims by more than 7,000 plaintiffs.
Tue, Apr. 8, 3:07 AM
- A jury has ordered Japan's Takeda (TKPYY) to pay $6B and Eli Lilly (LLY) $3B in punitive damages over allegations that they hid the cancer risks associated with the diabetes therapy Actos.
- However, Eli Lilly could be off the hook, as Takeda agreed to indemnify Lilly for any legal liability connected to Actos.
- In addition, the award is likely to be cut on appeal, as the Supreme Court has set limits on punitive verdicts.
- In two previous cases, judges quashed multi-million dollar awards against Actos.
- Notwithstanding, Takeda's shares slumped 5.2% in Tokyo.
Tue, Feb. 4, 8:28 AM
- Ten major pharmaceuticals companies are getting together with the National Institutes of Health and other organizations in a five-year partnership that will look to understand the science behind Alzheimer's, Type 2 diabetes, rheumatoid arthritis and lupus.
- In an unusual move, the normally secretive participants will share scientists, tissue, blood samples and data, with the aim being to identify targets for new drugs.
- The firms involved include Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), GlaxoSmithKline (GSK), Takeda (TKPHF) and Sanofi (SNY).
- Those that haven't joined include Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
Dec. 27, 2013, 7:51 AM
- "The company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam do not outweigh the potential risks,” Takeda (TKPHF) says, ending development of its late-stage GPR40 agonist TAK-875.
- The drug was tied to liver damage.
- The company had hoped the treatment would help offset revenue lost to generic Actos, the diabetes drug which at one time accounted for more than a quarter of Takeda's top-line.
- Shares fell 5%+ in Tokyo on the news.
Dec. 10, 2013, 2:27 PM
- Takeda's (TKPHF +1.4%) vedolizumab had a rather easy go of it Monday, as an FDA panel voted overwhelmingly that the drug should be approved as a maintenance therapy for Crohn's disease and as a treatment for Crohn's and ulcerative colitis in patients not helped by prior therapies.
- Nevertheless, the vote was far closer (12-9) regarding whether the treatment should be available as an early therapy.
- "The FDA's efficacy concerns stem from some up-and-down data in vedolizumab's pivotal trials," FierceBiotech's Damien Garde notes, before adding that, on the bright side, "the panel voted 21-0-0 that the company had adequately characterized the drug's risks of PML."
Dec. 1, 2013, 2:50 AM
- Japan's Takeda Pharmaceutical (TKPHF) has named 20-year GlaxoSmithKline veteran Christophe Weber as the candidate to become its next CEO.
- Assuming Takeda's shareholders approve the appointment of Weber, the French national is set to become the company's first non-Japanese leader in its 232-year history.
- Weber, who is the president of GSK's vaccines division in Belgium, will become Takeda's COO by April, its president in June, and its CEO in 2015. (PR)
There are no StockTalks on this stock yet.
TKPHF vs. ETF Alternatives
Research & Development, Manufacturing, Sales and Marketing, and Import/Export of Pharmaceutical Drugs, etc.
Other News & PR